AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium ...
Coherus BioSciences (CHRS) has entered into an asset purchase agreement dated December 2, 2024, with Intas Pharmaceuticals for the divestiture of the UDENYCA franchise for up to $558.4 million. This ...
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company NASDAQ: CHRS,) today announced that it has entered into an asset purchase agreement (the ...
In a significant ruling for pharmaceutical regulation in India, the Delhi High Court has reinstated the Indian government's ...
Coherus BioSciences (NASDAQ:CHRS) said it has entered into an asset purchase agreement with Intas Pharmaceuticals for the divestiture of the UDENYCA franchise for up to $558.4 million. Shares of the ...
GUANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today ...
On February 10, 2025, Bio-Thera Solutions, Ltd. announced that they entered into an exclusive licensing agreement with Intas Pharmaceuticals Ltd. to commercialize BAT2506 (golimumab), Bio-Thera’s ...
HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Triangle pharmaceutical firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results